{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chronic-obstructive-pulmonary-disease/prescribing-information/mucolytics/","result":{"pageContext":{"chapter":{"id":"1f101b12-c624-5d0c-9b55-c7fa2d40a3ed","slug":"mucolytics","fullItemName":"Mucolytics","depth":2,"htmlHeader":"<!-- begin field 4cc46cf7-2ba2-4129-82d9-e2a50137a2b4 --><h2>Mucolytics</h2><!-- end field 4cc46cf7-2ba2-4129-82d9-e2a50137a2b4 -->","summary":"","htmlStringContent":"<!-- begin item 3c04865b-7b1f-43cd-8ff5-95fddab09f87 --><!-- end item 3c04865b-7b1f-43cd-8ff5-95fddab09f87 -->","topic":{"id":"8e2a563d-c3b1-5ed5-a460-de2b3ffc8c0f","topicId":"e48489e8-63d1-4a04-bc5b-07e36a76af58","topicName":"Chronic obstructive pulmonary disease","slug":"chronic-obstructive-pulmonary-disease","lastRevised":"Last revised in October 2020","chapters":[{"id":"8441dfb8-d2f6-511c-abf6-23d0c8a600d0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5ccd2981-1bc9-5357-86d2-cbf578b57adb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2eb66d0c-0e3f-55c2-bb2f-ba47fdbd1bfd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8f4eeb38-3744-5824-a90c-82b0b8906580","slug":"changes","fullItemName":"Changes"},{"id":"f2cfeec1-2d2a-5d22-b569-42eb61ba7caa","slug":"update","fullItemName":"Update"}]},{"id":"d28cbe2c-ffc9-58ab-913c-3afa52c28841","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"99f07881-2c1a-5874-8cd2-3f10dcb385fa","slug":"goals","fullItemName":"Goals"},{"id":"85c2e06f-fe1e-532b-8752-0337ca19cfe3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f6fa4f07-a45d-5c3e-8c59-2054ea5ecd38","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"defe1786-7b6d-5c90-a7f4-0871262dd84f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6356570-e32f-5480-89d6-026b80bb055d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0433c46f-8e2f-53b3-a392-aca635b35160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"29a2fdef-c0c3-5bb6-9c12-21d649ed27bb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"715af617-76e1-5846-9262-1616f0003270","slug":"definition","fullItemName":"Definition"},{"id":"6f383baf-ff39-58db-b933-24b4c5feb5f8","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"7fe9ff8f-68ba-5f97-91ab-8d23c907b1cf","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4bcdbaec-2487-5733-812a-7ec514939f8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c7c94e20-91a7-5b3d-b8dd-0d4f8d5c023c","slug":"complications","fullItemName":"Complications"}]},{"id":"844f6e5f-bd6a-5d1d-8f3e-0980e52cd744","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"aa2453ae-c791-521b-9ead-ca40d5efae00","slug":"diagnosis-copd","fullItemName":"Diagnosis - COPD"},{"id":"93fac9cc-fc19-5440-8330-f6f56941ddb6","slug":"diagnosis-acute-exacerbation","fullItemName":"Diagnosis - acute exacerbation"}]},{"id":"b513a018-d7cf-53a1-9748-c7fa367312d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"4aafe1b6-b17a-51d8-a8f0-104880ac3722","slug":"stable-copd","fullItemName":"Scenario: Stable COPD"},{"id":"ef02510d-99b8-561a-b40c-8bfaab787b88","slug":"acute-exacerbation","fullItemName":"Scenario: Acute exacerbation"},{"id":"22cd95c6-b76a-5e58-8329-cfed9e9bf26e","slug":"end-stage-copd","fullItemName":"Scenario: End-stage COPD"},{"id":"f1d4be42-b98a-55de-860a-3be931c97c1c","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"651db25c-bc72-5eaa-b790-e5c86053d13c","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"51f6354b-2f19-59ca-889c-a9497e0223fc","slug":"muscarinic-antagonists","fullItemName":"Muscarinic antagonists"},{"id":"10bec3db-4371-5d92-a5e9-4f2300029732","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"f45aa048-e0b1-55dc-9f40-68f5af6d3b61","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"1f101b12-c624-5d0c-9b55-c7fa2d40a3ed","slug":"mucolytics","fullItemName":"Mucolytics"},{"id":"669a5030-cc7b-5a64-ba03-f05ca2dd60f3","slug":"theophylline","fullItemName":"Theophylline"},{"id":"2006f9b1-cca0-50cd-9c1e-99a6316048e4","slug":"antibiotics","fullItemName":"Antibiotics"}]},{"id":"81fd9c2f-91c3-5726-b50a-85fc169646d3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b91263e-7dc1-51aa-9976-bd92619d846e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ac29e092-9d36-550e-99e2-c6b478d21c00","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"737d1a20-607a-560b-8522-2ddb2237249b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bec938e3-108f-5f91-9c9b-2c289bae4e07","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dc4c2f7c-85ce-5ba5-a2ef-149ee8a9d54d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51ecdba0-ee93-5792-af12-b38cb8f06b8c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9ad1cd46-bf5b-505f-a6d9-bad7287adccc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"16f8816c-7200-58c0-aad5-862f37ba6756","slug":"doses","fullItemName":"Doses","depth":3,"htmlHeader":"<!-- begin field 968e2aae-6a7a-46cb-950c-be335cdc2519 --><h3>Which mucolytics can be prescribed?</h3><!-- end field 968e2aae-6a7a-46cb-950c-be335cdc2519 -->","summary":"","htmlStringContent":"<!-- begin item d8906406-e4d9-4a86-8ec3-ef07b37a8caf --><!-- begin field 87c9f898-17f1-49ab-ba76-1fc307a46497 --><ul><li>Carbocisteine and acetylcysteine are the oral mucolytics licensed for use in people with chronic obstructive pulmonary disease.</li><li>For carbocisteine the manufacturer recommends a starting dose of 2250 mg in divided doses, reducing to 1500 mg daily in divided doses when a satisfactory response is obtained.</li><li>For acetylcysteine, the manufacturer recommends a dose of 1 effervescent tablet of 600 mg once daily.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018p</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2019d</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>] </p><!-- end field 87c9f898-17f1-49ab-ba76-1fc307a46497 --><!-- end item d8906406-e4d9-4a86-8ec3-ef07b37a8caf -->","subChapters":[]},{"id":"e2f00a7d-db06-57e6-895c-252bc5e78094","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field b2f74be0-9f0b-4546-bf74-9e9b20103cb0 --><h3>What contraindications and cautions are important with carbocisteine?</h3><!-- end field b2f74be0-9f0b-4546-bf74-9e9b20103cb0 -->","summary":"","htmlStringContent":"<!-- begin item 85b56464-48c0-4379-b161-d70fa4f7b210 --><!-- begin field 0d2da5ec-5ec8-461e-9cab-1a24b882591f --><ul><li><strong>Do not prescribe carbocisteine to:</strong><ul><li>People with active peptic ulceration.</li><li>People with asthma or respiratory failure.</li><li>Women who are pregnant or breastfeeding.</li></ul></li><li><strong>Prescribe carbocisteine with caution to:</strong><ul><li>People with a history of peptic ulceration or those taking concomitant medications known to cause gastrointestinal bleeding.</li></ul></li><li><strong>Prescribe acetylcysteine with caution to:</strong><ul><li>People with a history of peptic ulceration.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018p</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2019d</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>] </p><!-- end field 0d2da5ec-5ec8-461e-9cab-1a24b882591f --><!-- end item 85b56464-48c0-4379-b161-d70fa4f7b210 -->","subChapters":[]},{"id":"313d76ff-e18a-5182-a58e-42c98b031109","slug":"drug-interations","fullItemName":"Drug interations","depth":3,"htmlHeader":"<!-- begin field 6b9d3274-3c11-45b7-8377-a8753575e509 --><h3>What drug interactions should be considered?</h3><!-- end field 6b9d3274-3c11-45b7-8377-a8753575e509 -->","summary":"","htmlStringContent":"<!-- begin item c4b3e08a-2620-42cc-9d19-fb53d48dccd9 --><!-- begin field be6ed406-ab6f-4a17-b944-2fa0635cf1a6 --><ul><li>The manufacturers state that combination of mucolytics with antitussives and/or substances that dry out secretions (atropinic) is not rational.</li><li>The manufacturer recommends that for acetylcysteine:<ul><li>The effervescent solution created using acetylcysteine should not be mixed with other drug solutions.</li><li>If oral antibiotics are required, these should be taken two hours before or after acetylcysteine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018p</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2019d</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>] </p><!-- end field be6ed406-ab6f-4a17-b944-2fa0635cf1a6 --><!-- end item c4b3e08a-2620-42cc-9d19-fb53d48dccd9 -->","subChapters":[]},{"id":"be789522-f88e-5505-af75-27e1b2ccbd5c","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 1ab08b2d-cb7b-4e2a-89f6-aa1400bfed2c --><h3>What important adverse effects are associated with mucolytics?</h3><!-- end field 1ab08b2d-cb7b-4e2a-89f6-aa1400bfed2c -->","summary":"","htmlStringContent":"<!-- begin item 28e65740-64ff-4e98-a0a1-aa1400bfec6b --><!-- begin field 9c967d08-102a-4584-8695-aa1400bfed2c --><ul><li><strong>The adverse effects of carbocisteine include:</strong><ul><li>Skin reactions including Stevens-Johnson syndrome and erythema multiforma.</li><li>Gastrointestinal bleeding and vomiting.</li></ul></li><li><strong>The adverse effects of acetylcysteine include:</strong><ul><li>Bronchospasm.</li><li>Skin reactions including Stevens-Johnson syndrome.</li><li>Dyspepsia.</li><li>Headache and tinnitus.</li><li>Diarrhoea, vomiting, nausea, gastrointestinal discomfort and stomatitis,</li><li>Hypotension.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018p</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2019d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>] </p><!-- end field 9c967d08-102a-4584-8695-aa1400bfed2c --><!-- end item 28e65740-64ff-4e98-a0a1-aa1400bfec6b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}